Why Axcelis Technologies Is Poised For Superior Growth: BofA Initiates With Buy Rating

BofA Securities analyst Duksan Jang initiated coverage on the shares of Axcelis Technologies, Inc. ACLS with a Buy rating and a price target of $225.

The analyst believes that the Street is underappreciating exposure to some of the fastest growing semis end markets, share gains in a rising $3 billion TAM and superior growth prospects over semi cap peers.

ACLS is a key beneficiary of emerging trailing-edge auto/industrial applications, and the analyst believes it has the potential to expand its share to 35% by CY25E, up from 28% in CY22.

Implant TAM should grow 10-15% CAGR, driven by rising and sustained demand for trailing-edge (older) processes, said the analyst.

Specifically, according to the analyst, the silicon carbide device market, where ACLS has the highest exposure, should grow >30% CAGR on strong demand visibility/ backlogs for emerging EV/power device tools.

ACLS is the 2nd largest implant provider (28% share) and is quickly gaining share via focus (100% of tool sales) and wide breadth of portfolio, noted the analyst.

While the analyst acknowledges ACLS stock has risen 120%+ YTD, it still trades at 19-20x CY24E earnings, below peers at 22x. 

The analyst believes ACLS should trade at the high-end of peers (16x-29x), given continued share gains and industry outgrowth.

Concentration of 30% - 50% of tool sales in China, deceleration of implant TAM and consumer weakness are seen as risks. 

The analyst thinks ACLS should trade at the high-end of peers (16x-29x), given continued share gains and industry outgrowth.

Price Action: ACLS shares are trading lower by 6.06% at $168.04 on the last check Friday.

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst ColorEquitiesNewsPrice TargetInitiationSmall CapMarketsAnalyst RatingsTrading IdeasGeneralBriefsExpert Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!